Objectives. To establish the rate of recurrent infection in RA patients recruited to the British Society for Rheumatology Biologics Register Rheumatoid Arthritis. Secondary objectives were to establish whether the organ class of index infection predicted future serious infection (SI).
Introduction
RA patients are at an increased risk of infection compared with healthy individuals [1] . The aetiology of infection risk in RA is multifactorial and relates to immune dysfunction, disease activity and immunosuppression [25] . Combination non-biologic DMARDs (nbDMARDs) and the expanding armamentarium of biologic drugs have revolutionized RA management; however, serious infec-tion (SI) associated with drug therapies remains a concern.
The baseline SI rate in nbDMARD-treated RA patients is estimated at 3% per annum [6] . The British Society for Rheumatology Biologics Register Rheumatoid Arthritis (BSRBR-RA) has previously reported a small but significantly increased risk of severe infection (20%) with TNF inhibitor (TNFi) therapy compared with nbDMARD therapies [6] . Similar findings have been reported from several international biologic drug registries [710] . Newer biologic agents targeting alternative immune pathways including abatacept, rituximab and tocilizumab have comparable safety and efficacy to TNFi drugs [11, 12] . If a patient experiences an SI while on biologic therapy, a clinical decision must be made regarding future immunosuppression. Therefore, recognizing the pattern of recurrence of infections may provide an important context.
We undertook an analysis of the BSRBR-RA and identified patients with SI while on anti-rheumatic therapy, and prospectively examined their risk of subsequent infection. Our aims were to: establish the rate of recurrent infection in patients recruited to the BSRBR-RA; determine whether the organ class of an index infection predicted the organ class of subsequent SI; and identify factors that predispose patients to infection.
Methods
The BSRBR-RA is a prospective observational cohort established in 2001 to evaluate the safety and efficacy of biologic drugs (including adalimumab, etanercept, infliximab, certolizumab-pegol, anakinra, rituximab and tocilizumab). The BSRBR-RA methodology has been described previously [13] . A comparison cohort of biologic-naïve RA patients with active disease (DAS28 >4. 
Baseline assessment
Baseline data collected at the time of recruitment to the register (for nbDMARD-treated patients) or start of biologic therapy included patient demographics, disease duration, DAS28 score, HAQ score, smoking status, current oral steroid use and comorbidity. Current and previous anti-rheumatic drug exposures were recorded.
Patient follow-up
Questionnaires were sent to supervising rheumatology teams and patients on a 6-monthly basis for the first 3 years of follow-up and annually thereafter (to rheumatology teams only) to collate information on adverse events and drug exposures. NHS Digital [previously NHS Information Centre (NHS-IC)] informed the BSRBR-RA of death in subjects recruited to the register.
Case definition
All patients registered within the BSRBR-RA with at least one episode of SI were included irrespective of drug exposure. SI was defined as an event requiring intravenous antibiotics, hospitalization or resulting in death. Incident cases of SI were collected from all three methods of patient follow-up. For inclusion in the analysis, patient-reported SI required verification by the supervising rheumatology team and completion of event-of-interest forms to provide further information about the SI event.
Infections were coded by Medical Dictionary for Regulatory Activities terminology and classified by two physicians (S.S./R.B.-M.) into seven categories (sepsis, lower respiratory, musculoskeletal, skin and soft tissue, gastrointestinal, genitourinary and other). Infections classified as other included unspecified viral, dental, ENT and upper respiratory tract infections. CNS and cardiac infections were also grouped as other infections; however, absolute numbers were small. Patients with multiple SI on the same day were categorized according to the most clinically significant infection (in the organ class order as listed above), adjudicated by the reviewing physicians. Admissions with recurrent SI occurring >14 days after the index infection were included as new events, re-admissions within 14 days with SI were considered as nonresolution of the initial episode and not re-coded. Patients were considered at risk until recurrent infection, death or last follow-up before June 2016, whichever came first.
Statistical methods
Characteristics of patients with and without SI infection during follow-up were tabulated and statistically significant imbalance tested using t-tests, MannWhitney U tests or Chi-square tests as appropriate. Incidence rates of SI, recurrent SI (of any class) and recurrent SI within the same organ class as the index infection were calculated. A Cox proportional hazards model was used to identify predictors of SI. Adjustments were made for age, gender, disease duration, baseline DAS28 score, smoking status, serological status and polypharmacy at baseline. Polypharmacy was considered as a surrogate measure of comorbidity. Treatment decisions, that is, whether to stop or continue a drug following an SI, were not considered in this analysis. Analyses were undertaken using Stata 14 (Statacorp LLC, Texas, TX, USA). The assumptions of the Cox model were tested graphically using NelsonAalen plots and using Schoenfeld residuals.
Results
In total, 21 943 subjects with 115 423 patient-years followup were registered in the BSRBR-RA, of whom 5289 subjects experienced at least one SI. The data cut-off date was 30 June 2016. At time of index infection, all patients were on DMARD or biologic therapy. The treatments were as follows: 1868 individuals on DMARDs only, 2764 receiving a TNFi, 520 receiving rituximab and 137 receiving tocilizumab. Baseline demographics are presented in Table 1 . The estimated annual rate of SI was 4.6% (95% CI: 4.5, 4.8). Respiratory tract infections were the most common (44% of all SI recorded). Patients who experienced SI (in any organ class) were older, more likely to be male, seropositive, steroid users and have higher baseline HAQ scores.
Patients with musculoskeletal infections were significantly more likely to be seropositive, current smokers and have longer disease duration compared with subjects suffering other classes of SI. Genitourinary infections were more frequent in women than men. Baseline steroid usage was higher amongst patients suffering sepsis compared with subjects suffering other classes of SI (Table 1) .
Following an index SI, the estimated annual rate of recurrent SI (in any organ class) increased to 14.2% (95% CI: 13.5, 14.8), averaged over the follow-up period. There was a considerable time varying risk with recurrent infections occurring soon after an index event. The highest risk of recurrent events appears to be within the first 3 months (Fig. S1 , available as supplementary data at Rheumatology online). In the first 12 months following an SI, the incidence of infection was 29.3% (95% CI: 27.6, 31.1). The organ class of recurrent infections mirrored the organ class of index infection, that is, in patients with an index respiratory tract infection, recurrent respiratory tract infections were more common compared with infections of other types ( Table 2 ). The organ class of index infection was associated with risk of recurrence. Subjects who experienced sepsis had the highest risk of a recurrent event (in any organ class): 19.7% per annum (95% CI: 15.1, 25.7).
In a multivariable model, compared with an index respiratory tract infection, an index episode of sepsis conferred a significantly increased hazard for recurrent SI in any organ [hazard ratio (HR) = 1.32, 95% CI: 1.00, 1.74; P = 0.02]. Increasing age was significantly associated with an increased risk of recurrent infection (HR for each decade older = 1.34, 95% CI: 1.27, 1.40). Subjects prescribed between 6 and 10 drugs at baseline had a 26% increased hazard of recurrent SI (HR = 1.26, 95% CI: 1.13, 1.41), increasing to 74% in patients treated with 11 or more drugs (HR = 1.74, 95% CI: 1.47, 2.07). Baseline DAS28 score, disease duration, seropositivity and current smoking were not significant predictors of infection recurrence (Fig. S2 , available as supplementary data at Rheumatology online).
Discussion
It has been shown previously that a history of SI is a strong predictor of subsequent SI, but what has not been shown before is that the organ class of the index event has a large impact on the likelihood of recurrent SI. In our analysis, patients who had an initial episode of sepsis had the highest risk of having a further SI, at 20% per annum. For those whose initial event was a musculoskeletal infection or gastrointestinal infection the risk of subsequent SI was significantly less, at 10%.
Consistent with the general population, urinary tract infections were more common in women than men, likely explained by anatomical differences [14] . Musculoskeletal infections were predicted by hallmarks of RA disease 14.9 (9.9)** severity (disease duration, seropositivity) as previously reported by Doran et al. [15] . Our data suggest a link between steroid usage and SI, particularly sepsis. We did not consider steroids and infection risk in detail due to challenges in assessing exposure accurately. Baseline oral steroid use was captured but intermittent steroid use (including parenteral administration) was not considered. Steroids have been reported to be strongly associated with SI in RA, despite systematic review and metaanalysis not drawing firm conclusions [15, 16] . Steroids are more likely to be prescribed to patients with more aggressive, recalcitrant disease; this group has a higher baseline infection risk and therefore there is potential for confounding by indication. Polypharmacy was our surrogate measure of comorbidity at baseline. Patients prescribed 6 or more drugs had a significantly increased risk of infection, increasing further if prescribed 11 or more drugs. Although the indication of prescribed therapies was not considered (immunosuppressive, preventative or prophylactic), polypharmacy has advantages over simple comorbidity scores. It offers indirect information on disease severity and avoids addition of multiple categorical variables into regression models.
Traditional predictors of infection (baseline DAS, disease duration, smoking, seropositivity) were not statistically significant predictors of recurrent SI; this may represent Berkson's paradox, a form of selection bias. Patients readmitted with SI were from an already at-risk group and therefore lack of association between traditional predictors of infection and recurrent SI may be spurious.
Strengths
To our knowledge, this is the first study that has quantified the burden of recurrent SI in a contemporary, real world representative RA cohort. The large sample size, robust coding of disease severity and adverse events enabled indepth analysis of recurrent SI, a significant and clinically relevant problem.
Limitations
In patients coded with multiple SI events on the same day, episodes were classified according to the clinically most serious and relevant SI. It was not possible to access individual discharge summaries for each hospitalized episode. We acknowledge the potential heterogeneity in infection severity within each organ class. No adjustments were made for length of hospital stay (a surrogate of infection severity), as social factors including delayed discharge may have inadvertently influenced results. The cohort studied was highly skewed towards patients with severe disease requiring biologic therapy (80% of the patients were recruited at the point of starting a biologic) and therefore may not be representative of a standard RA cohort. The impact of individual immunosuppressive drug exposures on recurrent infection risk was not considered in this analysis; this is a focus for future research.
Conclusions
Recurrent infections in RA are common; 14% of RA patients with an index SI will experience a recurrent event per year during follow-up, with the risk greatest within the first 12 months of follow-up (29%). The recurrence rate of infection is influenced by the index infection organ class; approximately one in five RA patients with sepsis will suffer a second SI per annum.
RA patients with a history of infection are a complex group to manage. When choosing a biologic for a patient without prior history of infection, small differences in relative risk may have little clinical significance when absolute rates of infection are considered. In patients with a prior history of infection, even small differences in relative infection risk may become significant. Further research needs to be undertaken to understand the patterns of The number of patient-years of follow-up. The annualized rate of the primary infection in the whole cohort. The recurrence rate of the index event.
f The overall recurrent infection rate in people who experienced a primary event. To interpret this, rates in column 5 can be compared with organ specific rates in column 4. Rates in column 6 can be compared with the overall infection rate in column 4. recurrent infection and to appreciate the nuances in differential infection profiles of immunosuppressive drugs, to promote safe therapeutic decisions and promote personalization of care.
